RxDoctor Payments Data

Mary Ann Williamson, MD

Cardiovascular Disease · Doylestown, PANPI 1598931206

Payments from drug & device makers

$2,188in general payments, 2019–2025

Across 130 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$532
  • Pfizer$240
  • E.r. Squibb & Sons, L.L.C.$222
  • Amgen$218
  • AstraZeneca$175
  • Boehringer Ingelheim$136
  • plus $665 from 17 others

What the payments were for

  • Food & beverage$2,188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,188 in reported general payments places this provider in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$225,465
Medicare patients
1,451
Services billed
3,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban582$690,676
FarxigaDapagliflozin Propanediol89$109,608
XareltoRivaroxaban78$106,832
EntrestoSacubitril/Valsartan73$97,165
JardianceEmpagliflozin71$62,006
Repatha SureclickEvolocumab41$57,724
Praluent PenAlirocumab19$23,727
Metoprolol Succinate857$16,435
VascepaIcosapent Ethyl31$15,440
Rosuvastatin Calcium532$8,675
Dabigatran EtexilateDabigatran Etexilate Mesylate37$8,126
Icosapent Ethyl14$8,046
Atorvastatin Calcium526$7,248
Ezetimibe206$5,061
Diltiazem 12hr ErDiltiazem Hcl14$4,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$240$690,676582 claims
AstraZenecaFarxiga$175$109,60889 claims
Johnson & JohnsonXarelto$54$106,83278 claims
NovartisEntresto$532$97,16573 claims
Boehringer IngelheimJardiance$136$62,00671 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →